Compare Novartis AG (NVS) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Novartis AG trades at $139.89 (market cap $262.64B), while Vanguard Total Stock Market Index Fund ETF trades at $376.45. The key difference: Novartis AG pays a 3.44% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VTI | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | — |
52-Week High | $168.62 | $384.30 |
52-Week Low | $121.80 | $311.68 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
VTI trades at $377.60, down 0.56% with neutral technical signals. The ETF maintains broad U.S. market exposure across 3,515 stocks with a minimal 0.03% expense ratio. Recent institutional activity includes DMC Group's $794,000 investment in Q2 2026, while technical indicators show support at $375 and resistance at $379.
Long-term outlook remains positive given historical 10% annual market returns, though concentration risk exists with top ten holdings representing one-third of assets. Market sentiment favors VTI for diversification amid potential volatility, with analysts highlighting its core portfolio role for 20-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
